1
Return

Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models

delete2025-02-03
delete0
delete
OA
AI
H
Hiroyuki Kogai
S
Shuntaro Tsukamoto
M
M Koga
M
Masayuki Miyano
T
Tsuyoshi Akagi
A
Atsumi Yamaguchi
K
Kiyoshi Mori
K
Kunihito Gotoh
Y
Youya Nakazawa *
DOI:10.1158/1535-7163.MCT-24-0444delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Despite remarkable advances in cancer treatment, most solid cancers remain difficult to cure. We recently developed an antibody-drug conjugate (ADC; 84-EBET) for pancreatic cancer by using the carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) antibody #84.7 and the bromodomain and extra-terminal (BET) protein degrader EBET. In this study, we showed the overexpression of CEACAM6 in colorectal, lung, and breast cancers and the broad-spectrum efficacy of 84-EBET in mouse models of these cancers. In vitro assays using cancer organoids and cell lines of colorectal, lung, and breast cancers revealed that 84-EBET was more potent than ADCs with known approved payloads-DXd, SN38, and monomethyl auristatin E-or standard chemotherapies. In mouse studies, a single injection of 84-EBET induced marked regression of colorectal-, lung-, and breast cancer patient-derived xenograft tumors and cell line-derived xenograft tumors. Moreover, in mouse syngeneic colorectal cancer, lung cancer, and breast cancer models resistant to PD-1 antibody, the combination of 84-EBET and PD-1 antibody induced complete regression of most tumors. Mechanistically, 84-EBET degraded bromodomain-containing protein 4 in both cancer and stromal cells via bystander efficacy. It decreased stromal inflammatory phenotypes and increased activated T-cell numbers in tumors. These results demonstrate that delivering BET protein degraders to tumors and their microenvironments via a CEACAM6-targeted ADC may be effective against a wide range of solid cancers.
Keywords:
CONSENSUS MOLECULAR SUBTYPES
MEDIATED DELIVERY
BRD4
FIBROBLASTS

Journal

Molecular Cancer Therapeutics cover
Molecular Cancer Therapeutics
IF:
5.5
Papers:
9.0K
Citations:
2.0W

Organization

E
eisai co ltd
Scholars:
2.2K
Papers: 1.2K
Citations: 0
O
Osaka National Hospital
Scholars:
1.1K
Papers: 1.1K
Citations: 914
Cited Papers

Cited Papers

Citing Papers

Citing Papers